Get started
Author

Xiaqin Cheng

Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer
2022 · Wei Wei, Xiaohua Ban, et al. · Journal for ImmunoTherapy of Cancer · 43
PDF
Overall survival according to time-of-day of combined immuno-chemotherapy for advanced gastric cancer: a propensity score-matched analysis
2025 · Chong Cheng, Xiaqin Cheng, et al. · Frontiers in Immunology · 8
PDF
A novel secondary ALK gene mutation which resistant to second-generation TKIs: a case report and literature review
2024 · Xiaqin Cheng, Jia Liu, et al. · Frontiers in Oncology · 6
PDF
Going from 3D/3D to 2D/3D registration for noncoplanar setup verification in intracranial single-isocenter multiple-target hypofractionated stereotactic radiotherapy: comparison between kilo-voltage/mega-voltage image pairs and noncoplanar cone-beam computed tomography
2023 · Jialu Lai, Shoupeng Liu, et al. · Quantitative Imaging in Medicine and Surgery · 3
PDF
Anlotinib plus sintilimab in patients with recurrent advanced endometrial cancer: A prospective open-label, single-arm, phase II clinical trial.
2021 · Wei Wei, Xiaohua Ban, et al. · Journal of Clinical Oncology · 2
Outcomes of Consolidative or Salvage Radiotherapy following Systemic Treatment for Advanced Malignant Pleural Mesothelioma: Retrospective and Propensity Score Matching Analysis
2025 · Xiaqin Cheng, Jia Liu, et al. · SSRN Electronic Journal
Detection of molecular signatures of homologous recombination deficiency in endometrial cancer (180)
2022 · Xiaqin Cheng, Ya Qiu, et al. · Gynecologic Oncology
Outcomes of Lymphadenectomy for Early-Stage Mucinous Ovarian Cancer: A Retrospective Study Based on Surveillance, Epidemiology, and End Results (SEER) Database
2022 · Xiaqin Cheng, Zhen Zeng, et al.
PDF
Works count: 8
Citation count: 62
H-index: 3
I10-index: 1
Year
Topic
Type